Abstract
Brain arteriovenous malformations (bAVM) have a low incidence of~1 per 100 000 per year in unselected populations, and the prevalence in adults is 0.14–0.5%. However, they have been in the scope of neuroendovascular specialists since the early times of the specialty because of their substantial risk of intracranial bleeding, especially in young people.1–4 Despite that, the management of bAVMs is still controversial, and there is no consensus on their treatment, particularly if they are unruptured.

This publication has 36 references indexed in Scilit: